Meeting the recommended leisure-time physical activity level was associated with a 30% reduced all-cause mortality risk at low pollution rates but only 12% to 15% at higher pollution rates.

Andrew Nixon, spokesperson for HHS, confirmed that the FDA was reviewing deaths potentially associated with the COVID-19 vaccine.

The FDA is "rigorously reviewing the available data" regarding the safety of 2 monoclonal antibody products for RSV in infants.

Young-onset hypertension increases the risk of cardiovascular and kidney outcomes compared with late-onset hypertension in type 2 diabetes.

COVID-19, RSV, and influenza immunizations show continued safety and substantial effectiveness against hospitalization across various populations.

The CDC's annual report on abortion trends has been delayed until the spring, but nongovernment groups produced similar research.

Investigators evaluated the risk for hepatocellular carcinoma after direct-acting antivirals (DAA)-cured hepatitis C virus (HCV) in DAA-naive adults with HIV-HCV coinfection and advanced fibrosis.

Disease disclosure helps mediate the effect of discrimination on internalized stigma among individuals with IBD.

Lower arterial pressure during septic shock is associated with higher mortality and kidney injury among patients with cirrhosis.

Plecanatide significantly improves abdominal pain, bloating, and bowel movement frequency among young adults with IBS-C, supporting a novel trisymptom endpoint.

Tyruko (natalizumab-sztn), a biosimilar to Tysabri (natalizumab), has been made available by Sandoz, according to developer Polpharma Biologics.

The FDA has approved Linzess (linaclotide) for treatment of irritable bowel syndrome with constipation (IBS-C) in patients 7 years of age and older.